Singapore Welcomes IASO Bio's Pioneering BCMA CAR-T Therapy
IASO Bio’s done it—they've taken a leap into Singapore with their fully human BCMA-targeted CAR-T cell therapy, FUCASO. November 3 was the official launch day, a big moment in Southeast Asia’s healthcare hub. And we're not just talking any therapy. This is a world-first fully human BCMA CAR-T hitting Singapore's market after getting the nod from the Health Sciences...
Continue Reading